Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell, Francine K. Welty, Michael Miller, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2022) Vol. 42, Iss. 6
Open Access | Times Cited: 397

Showing 1-25 of 397 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1159
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah‐Kheong Chan, Kee Huat Chuah, Ruveena Bhavani Rajaram, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 197-213
Open Access | Times Cited: 274
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2024), pp. gutjnl-330595
Open Access | Times Cited: 250
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 153
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 100
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 75
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
Arun J. Sanyal, Vlad Ratziu, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1110-1120
Open Access | Times Cited: 62
Liver disease is a significant risk factor for cardiovascular outcomes – A UK Biobank study
Adriana Roca‐Fernández, Rajarshi Banerjee, Helena Thomaides‐Brears, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1085-1095
Open Access | Times Cited: 58
Natural history of metabolic dysfunction-associated steatotic liver disease
Vasileios Lekakis, George Papatheodoridis
European Journal of Internal Medicine (2023) Vol. 122, pp. 3-10
Closed Access | Times Cited: 58
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu, Qingxing Xie, Xiaohui Pan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 47
A healthy lifestyle, Life's Essential 8 scores and new-onset severe NAFLD: A prospective analysis in UK Biobank
Panpan He, Yanjun Zhang, Ziliang Ye, et al.
Metabolism (2023) Vol. 146, pp. 155643-155643
Closed Access | Times Cited: 43
Diabetes mellitus—Progress and opportunities in the evolving epidemic
E. Dale Abel, Anna L. Gloyn, Carmella Evans‐Molina, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3789-3820
Closed Access | Times Cited: 34
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019
Pojsakorn Danpanichkul, Kanokphong Suparan, Priyata Dutta, et al.
Metabolism (2024) Vol. 158, pp. 155958-155958
Closed Access | Times Cited: 29
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S59-S85
Closed Access | Times Cited: 18
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 16
The oral-gut microbiota axis: a link in cardiometabolic diseases
Qian Xu, Wenting Wang, Yiwen Li, et al.
npj Biofilms and Microbiomes (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
J Bernhard, L Galli, Walter S. Speidl, et al.
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Open Access | Times Cited: 2
Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects
Søren Møller, Nina Kimer, Jens D. Hove, et al.
European Journal of Preventive Cardiology (2025)
Closed Access | Times Cited: 2
Management of NAFLD in primary care settings
Vincent Wai‐Sun Wong, Shira Zelber‐Sagi, Kenneth Cusi, et al.
Liver International (2022) Vol. 42, Iss. 11, pp. 2377-2389
Closed Access | Times Cited: 53
Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease
Olufunto O. Badmus, Terry D. Hinds, David E. Stec
Current Hypertension Reports (2023) Vol. 25, Iss. 8, pp. 151-162
Open Access | Times Cited: 40
DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates
Pengxiang Qu, Oren Rom, Ke Li, et al.
Cell Metabolism (2023) Vol. 35, Iss. 5, pp. 742-757.e10
Open Access | Times Cited: 38
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
Anders Mellemkjær, Mikkel Breinholt Kjær, David Haldrup, et al.
European Journal of Internal Medicine (2023) Vol. 122, pp. 28-34
Open Access | Times Cited: 36
Metabolic dysfunction-associated steatotic liver disease and the heart
Stan Driessen, Sven Francque, Stefan D. Anker, et al.
Hepatology (2023)
Open Access | Times Cited: 31
Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction–Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study
Ki‐Chul Sung, Tae Kyung Yoo, Mi Yeon Lee, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2023) Vol. 43, Iss. 3, pp. 482-491
Open Access | Times Cited: 23
Remnant cholesterol has a non-linear association with non-alcoholic fatty liver disease
Jingfei Chen, Yingjie Su, Xin Su, et al.
Diabetes Research and Clinical Practice (2023) Vol. 201, pp. 110733-110733
Closed Access | Times Cited: 23
Page 1 - Next Page

Scroll to top